Larotrectinib Monotherapy - Paediatric. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Larotrectinib Monotherapy - Paediatric, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 01/02/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/760%20larotrectinib-monotherapy-paediatric.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have no satisfactory treatment options	3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	v::NTRK1	Any solid tumor	Larotrectinib
Sensitivity (+)	v::NTRK2	Any solid tumor	Larotrectinib
Sensitivity (+)	v::NTRK3	Any solid tumor	Larotrectinib